Chemiluminescent Microparticle Immunoassay Helps Diagnose Rheumatoid Arthritis
|
By LabMedica International staff writers Posted on 06 Nov 2009 |
|
A chemiluminescent microparticle immunoassay (CMIA) provides semiquantitative determination of the Immunoglobin G (IgG) class of autoantibodies specific to cyclic citrullinated peptide (CCP) in human serum or plasma. This product is for in vitro diagnostic use only.
Many patients with rheumatoid arthritis (RA) develop an immune response against proteins containing citrulline long before they present symptoms of the disease. Detecting the level of these antibodies earlier in the disease continuum, in conjunction with other clinical information, is critical to the early diagnosis of the disease.
The new assay was developed by Axis-Shield (Dundee, UK) to run on Abbott's (Abbott Park, IL, USA) Architect i1000SR and i2000SR systems. The US Food and Drug Administration (FDA; Silver Spring, MD, USA) has granted 510(k) clearance for an antibody cyclic-citrullinated peptide, or chemiluminescent microparticle immunoassay to run on the Architect systems. The anti-CCP assay is already approved and available on the Abbott Architect systems outside the United States.
Abbot's Architect family of analyzers includes the i1000SR and i2000SR for immunoassay testing, the c4000, c8000, and c16000 for clinical chemistry testing, and the ci4100, ci8200, and ci16200 integrated immunoassay/chemistry systems. Abbott's technologies include the Robotic Sample Handler to prioritize emergency tests; sample clot and bubble detection to verify sampling integrity; and FlexRate and ChemiFlex assay technologies. Architect systems use identical easy-to-use software and common reagents across all members of the family.
Abbott Diagnostics offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices, and clinics. The company's diagnostic products offer customers automation, convenience, cost effectiveness, and flexibility. Abbott develops treatments and diagnostics for immunologic diseases, including rheumatoid arthritis. The Architect integrated platform provides RA testing including anti-CCP, Rheumatoid Factor, and C-reactive protein (CRP).
Related Links:
Axis-Shield
Abbott
US Food and Drug Administration
Many patients with rheumatoid arthritis (RA) develop an immune response against proteins containing citrulline long before they present symptoms of the disease. Detecting the level of these antibodies earlier in the disease continuum, in conjunction with other clinical information, is critical to the early diagnosis of the disease.
The new assay was developed by Axis-Shield (Dundee, UK) to run on Abbott's (Abbott Park, IL, USA) Architect i1000SR and i2000SR systems. The US Food and Drug Administration (FDA; Silver Spring, MD, USA) has granted 510(k) clearance for an antibody cyclic-citrullinated peptide, or chemiluminescent microparticle immunoassay to run on the Architect systems. The anti-CCP assay is already approved and available on the Abbott Architect systems outside the United States.
Abbot's Architect family of analyzers includes the i1000SR and i2000SR for immunoassay testing, the c4000, c8000, and c16000 for clinical chemistry testing, and the ci4100, ci8200, and ci16200 integrated immunoassay/chemistry systems. Abbott's technologies include the Robotic Sample Handler to prioritize emergency tests; sample clot and bubble detection to verify sampling integrity; and FlexRate and ChemiFlex assay technologies. Architect systems use identical easy-to-use software and common reagents across all members of the family.
Abbott Diagnostics offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices, and clinics. The company's diagnostic products offer customers automation, convenience, cost effectiveness, and flexibility. Abbott develops treatments and diagnostics for immunologic diseases, including rheumatoid arthritis. The Architect integrated platform provides RA testing including anti-CCP, Rheumatoid Factor, and C-reactive protein (CRP).
Related Links:
Axis-Shield
Abbott
US Food and Drug Administration
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Thyroid Test
Anti-Thyroid EIA Test
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Molecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Microbiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more
Pathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more
